Clinical trials: Sexually Transmitted Infections
Hepatitis C Virus Genotype-1
A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1
The purpose of this study is to evaluate the safety and tolerability of TMC435 along with pegylated interferon alpha-2a (PegIFNα-2a) and ribavirin (RBV) triple therapy in hepatitis C virus genotype-1 infected subjects…
- Trial name
- NCT01479868
- Testing
- TMC435, Pegylated interferon alpha-2a, Ribavirin
- Where
- 32 sites in United States, Canada and 6 more
- Volunteers
- 109 people
- Sponsor
- Janssen R&D Ireland
Alcohol Use Disorder, Depression
Zambia Common Elements Treatment Approach Pilot Study
This is a randomized controlled trial (RCT) evaluating the effectiveness of an alcohol brief intervention alone compared to the brief intervention plus an evidence-based psychotherapy (CETA) in reducing alcohol misuse and…
- Conditions
- Alcohol Use Disorder, Depression, Post-traumatic Stress Disorder, HIV/AIDS
- Trial name
- ZCAP (NCT03966885)
- Testing
- Brief Intervention, Common Elements Treatment Approach (CETA)
- Where
- Zambia
- Volunteers
- 160 people
- Sponsor
- Columbia University
HIV Infection
Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use
The overall objective is to determine the influence of timing of ART initiation and alcohol consumption on HIV disease course. ART initiation immediately after HIV infection largely results in smaller HIV reservoir and lower…
- Trial name
- MERLIN (NCT02744040)
- Testing
- ART initiation at time of HIV diagnosis, ART at 24 weeks
- Where
- Peru
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
HIV Infections
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
The purpose of this study was to examine the pharmacokinetics, safety, and tolerability of abacavir/dolutegravir/lamivudine dispersible and immediate release tablets in children living with HIV less than 12 years of age.
- Trial name
- NCT03760458
- Testing
- Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets, Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)
- Where
- 14 sites in United States, Botswana and 2 more
- Volunteers
- 57 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus
Antiretroviral Improvement Among Medicaid Enrollees
This study will evaluate whether a new program will affect how often human immunodeficiency virus (HIV) antiretroviral therapy (ART) prescriptions are filled and whether the program improves the health of people living with HIV.
- Trial name
- AIMS (NCT05477485)
- Testing
- Experimental: AIMS program - patient, No Intervention/Usual care
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Virginia Commonwealth University
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency
Body Composition and Adipose Tissue in HIV
In this study, the investigators will examine the effect of therapy with the Growth Hormone Releasing Hormone (GHRH) analog tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity.
- Conditions
- HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
- Trial name
- NCT03226821
- Testing
- Tesamorelin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Hiv, HIV Infections
Effect of N-803 on B Cell Follicles in Antiretroviral Treated HIV Disease
N-803 has demonstrated ability to reactivate HIV from latency and can activate T cells and NK cells to clear those cells, thus reducing the reservoir.
- Conditions
- Hiv, HIV Infections, AIDS
- Trial name
- NCT04808908
- Testing
- N-803
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Minnesota
Medication Adherence
Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non-Adherence (ENLIGHTEN)
This is a pilot study to assess the feasibility, acceptability and appropriateness of delivery of the investigational "MedViewer" intervention in adult patients living with HIV who have been prescribed antiretroviral (ARV)…
- Trial name
- ENLIGHTEN (NCT04232540)
- Testing
- MedViewer report
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections, HIV-1
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
The purpose of this study is to provide etravirine (ETR) through this trial until participants can be switched to locally available ETR-based treatment regimens (that is, commercially available and reimbursed, or accessible…
- Trial name
- NCT00980538
- Testing
- Etravirine
- Where
- 29 sites in United States, Argentina and 9 more
- Volunteers
- 180 people
- Sponsor
- Janssen Sciences Ireland UC
HIV-1-infection, Alcohol Drinking
Acute Neural and Immune Effects of Alcohol in People Living With HIV Infection
This study will examine whether moderate alcohol use in the context of HIV infection exacerbates inflammatory signaling in the immune system and brain.
- Trial name
- NCT04050735
- Testing
- Alcohol, ethyl, moderate dose
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Brown University
Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
This phase II trial studies the side effects of a cord blood transplant using dilanubicel and to see how well it works in treating patients with human immunodeficiency virus (HIV) positive hematologic (blood) cancers.
- Conditions
- Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT04083170
- Testing
- Fludarabine, Cyclophosphamide, Thiotepa
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Fred Hutchinson Cancer Center
HIV Infections
Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women
Men who have sex with men (MSM) have an increased risk of developing anal human papillomavirus (HPV) infections, which can be a risk factor for anal cancer. HIV-infected women are also at risk of anal cancer.
- Trial name
- NCT01461096
- Testing
- Quadrivalent HPV Vaccine
- Where
- 24 sites in United States, Brazil and 1 more
- Volunteers
- 575 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infections, Papillomavirus
Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females
This Post Marketing Surveillance (PMS) will collect safety data on the use of GSK Biologicals' human papillomavirus (HPV) vaccine in the local target population of females as per the regulations of the Korean Food and Drugs…
- Trial name
- NCT01101542
- Testing
- Cervarix., Data collection
- Where
- 2 sites in South Korea
- Volunteers
- 3,091 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cardiovascular Diseases, Hepatitis C
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
This is an interventional, non-randomized, controlled prospective study to treat HCV in mono-infected and HIV co-infected individuals and compare cardiovascular risk outcomes to HIV mono-infected controls.
- Conditions
- Cardiovascular Diseases, Hepatitis C, Hiv
- Trial name
- CHROME (NCT03823911)
- Testing
- Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI
- Where
- 2 sites in United States
- Volunteers
- 87 people
- Sponsor
- University of Maryland, Baltimore
Infections, Papillomavirus
Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.
This study will collect safety data of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in healthy females of Chinese origin who are unable to receive all three doses of commercially available HPV vaccine before…
- Trial name
- NCT00811798
- Testing
- Cervarix
- Where
- Hong Kong
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Immunodeficiency Virus
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
The purpose of the study is to assess: 1 safety and tolerability of adenovirus serotype 26 (Ad26) prime and Modified Vaccinia Ankara (MVA) boost versus placebo in participants on suppressive antiretroviral therapy (ART) that was…
- Trial name
- NCT02919306
- Testing
- Ad26.Mos.HIV, MVA-Mosaic
- Where
- Thailand
- Volunteers
- 27 people
- Sponsor
- Janssen Vaccines & Prevention B.V.
HIV Infections, Hyperlipidemia
Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin
Pravastatin (Pravachol) is approved by the Food and Drug Administration (FDA) and is used to treat high cholesterol. Darunavir (Prezista) and ritonavir (Norvir) are approved by the Food and Drug Administration (FDA) to treat HIV…
- Trial name
- NCT00630734
- Testing
- Pravastatin, Darunavir, Ritonavir
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Human Papillomavirus Infection
Lubricant Investigation in Men to Inhibit Transmission of HPV Infection
The LIMIT-Study is a placebo-controlled, double-blinded randomized controlled trial designed to explore the efficacy of a carrageenan-based lubricant as a topical microbicide for preventing HPV acquisition.
- Trial name
- LIMIT-HPV (NCT02354144)
- Testing
- Carrageenan-based gel, Control gel
- Where
- Canada
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- McGill University
HIV Infections, Hepatitis C
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)
The primary objective of this trial is to compare the efficacy of boceprevir (SCH 503034) 800 mg three times a day (TID) orally (PO) in combination with peginterferon alfa-2b (PegIFN-2b) 1.5 µg/kg weekly (QW) subcutaneously (SC)…
- Conditions
- HIV Infections, Hepatitis C, HCV Infection
- Trial name
- NCT00959699
- Testing
- PegIFN-2b, RBV, Boceprevir
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Gonococcal Infection
Experimental Human Infection With Neisseria Gonorrhoeae
This is a Phase 1, interventional, non-randomized, experimental infection model study with healthy adult males adults (N=32) between the ages of 18-36 at study enrollment.
- Trial name
- NCT03840811
- Testing
- Cefixime, Ceftriaxone, Ciprofloxacin
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.